Based on our Pharmacor Hepatitis C Virus advisory service, Decision Resources is offering an exclusive analyst call entitled The Future is Now – How Will the Launches of Victrelis & Incivek Impact the Market and the Regulatory Landscape for Hepatitis C Virus?
Date & Time
Recorded live on Thursday, June 2, 2011
This 15-minute analyst call, presented by Decision Resources Analyst Seamus Levine-Wilkinson, Ph.D., will answer the following questions:
- What was the advisory committee's assessment of Victrelis and Incivek, and how will these agents be used for treatment of chronic HCV?
- How will Roche's plan to market Victrelis in combination with its market leading interferon-alfa, Pegasys, impact the HCV drug market?
- Will follow-on HCV therapeutics face stricter regulatory scrutiny?
- Through 2019, which HCV agents are expected to launch and how will they compete against Victrelis and Incivek?
This analyst call was held on June 2, 2011. Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.